Wednesday, May 24, 2017 9:32:43 PM
"She said after a six-month period of KU’s shares being frozen, the university will be able to make an investment decision on whether to sell them or hold the shares. She declined to say how many shares KU owns, saying that information about KU’s equity is part of a confidential licensing agreement."
Recent SVRA News
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 10/24/2024 06:02:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/22/2024 08:10:52 PM
- Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV • Business Wire • 10/22/2024 12:05:00 PM
- Savara Announces New Employment Inducement Grant • Business Wire • 10/18/2024 08:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 10/01/2024 08:37:38 PM
- Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting • Business Wire • 10/01/2024 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/27/2024 08:35:29 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/27/2024 08:33:27 PM
- Savara Announces New Employment Inducement Grant • Business Wire • 09/27/2024 08:05:00 PM
- Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) • Business Wire • 09/27/2024 12:05:00 PM
- Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately • Business Wire • 09/24/2024 12:05:00 PM
- Savara to Host Analyst and Investor Webinar on September 30, 2024 • Business Wire • 09/23/2024 12:05:00 PM
- Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024 • Business Wire • 09/08/2024 10:45:00 AM
- Savara Announces New Employment Inducement Grant • Business Wire • 09/06/2024 08:05:00 PM
- Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference • Business Wire • 09/03/2024 08:05:00 PM
- Savara Announces New Employment Inducement Grant • Business Wire • 08/16/2024 08:05:00 PM
- Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 • Business Wire • 08/15/2024 12:05:00 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/15/2024 12:45:41 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 08:05:21 PM
- Savara Reports Second Quarter 2024 Financial Results and Provides Business Update • Business Wire • 08/12/2024 08:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/26/2024 08:09:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/22/2024 08:16:53 PM
- Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock • Business Wire • 06/28/2024 12:50:00 PM
- Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) • Business Wire • 06/26/2024 10:30:00 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM